Uterine Artery Embolization for Symptomatic Fibroids

This study has been completed.
Sponsor:
Information provided by:
University of Manitoba
ClinicalTrials.gov Identifier:
NCT00354471
First received: July 19, 2006
Last updated: February 4, 2009
Last verified: July 2006
  Purpose

This study will evaluate the safety, efficacy , quality of life and patient satisfaction of uterine artery embolization for the treatment of symptomatic uterine fibroids. It will provide useful information in the development od guidelines in patient selection, procedural management and subsequent follow up.


Condition Intervention Phase
Uterine Fibroids
Menorrhagia
Adenomyosis
Procedure: Uterine Artery Embolization
Phase 3

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Short and Long Term Outcomes of Uterine Artery Embolization.

Resource links provided by NLM:


Further study details as provided by University of Manitoba:

  Eligibility

Ages Eligible for Study:   18 Years to 60 Years
Genders Eligible for Study:   Female
Criteria

Inclusion Criteria:

  • Symptoms related to the pressence of uterine fibroids serious enough to consider surgical options
  • Confirmation of fibroids by endovaginal and transabdominal ultrasound

Exclusion Criteria:

  • Pedunculated fibroids
  • Desire for fertility
  • Carcinoma of pelvic organs
  • Previous pelvic irradiation
  • Bleeding diathesis and vasculitis
  • History of allergiy to contrst medium
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00354471

Locations
Canada, Manitoba
Health Sciences Centre
Winnipeg, Manitoba, Canada, R3E 3P4
Sponsors and Collaborators
University of Manitoba
Investigators
Principal Investigator: Richard S Boroditsky, MD University of Manitoba
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00354471     History of Changes
Other Study ID Numbers: B2000 115
Study First Received: July 19, 2006
Last Updated: February 4, 2009
Health Authority: Canada: Health Canada

Additional relevant MeSH terms:
Adenomyosis
Leiomyoma
Myofibroma
Menorrhagia
Neoplasms, Muscle Tissue
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Connective Tissue
Connective Tissue Diseases
Uterine Hemorrhage
Uterine Diseases
Genital Diseases, Female
Menstruation Disturbances
Pathologic Processes

ClinicalTrials.gov processed this record on September 29, 2014